Literature DB >> 15383607

Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis.

Laura Boos1, Iain L Campbell, Robert Ames, Rick A Wetsel, Scott R Barnum.   

Abstract

The C3aR is expressed throughout the CNS and is increased in expression on glial cells during CNS inflammation. However, the role that C3a and the C3aR play in chronic inflammation, such as in the demyelinating disease experimental autoimmune encephalomyelitis (EAE), remains unclear. We show in this study that deletion of the C3aR is protective in myelin oligodendrocyte glycoprotein-induced EAE in C57BL/6 mice. C3aR-deficient (C3aR(-/-)) mice had a significantly attenuated course of EAE compared with control mice during the chronic phase of the disease. Immunohistochemical analysis demonstrated modestly reduced macrophage and T cell infiltration in the spinal cords of C3aR(-/-) mice. To examine the role of C3a in EAE, we developed a transgenic mouse that expresses C3a exclusively in the CNS using the glial fibrillary acidic protein (GFAP) promoter. We observed that C3a/GFAP mice had exacerbated EAE during the chronic phase of the disease, with significant mortality compared with nontransgenic littermates. C3a/GFAP mice had massive meningeal and perivascular infiltration of macrophages and CD4(+) T cells. These studies indicate that C3a may contribute to the pathogenesis of demyelinating disease by directly or indirectly chemoattracting encephalitogenic cells to the CNS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383607     DOI: 10.4049/jimmunol.173.7.4708

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Carboxypeptidase N-deficient mice present with polymorphic disease phenotypes on induction of experimental autoimmune encephalomyelitis.

Authors:  Xianzhen Hu; Rick A Wetsel; Theresa N Ramos; Stacey L Mueller-Ortiz; Trenton R Schoeb; Scott R Barnum
Journal:  Immunobiology       Date:  2013-08-23       Impact factor: 3.144

Review 2.  The role of complement in danger sensing and transmission.

Authors:  Jörg Köhl
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

3.  Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease.

Authors:  Alexander J Szalai; Xianzhen Hu; Jillian E Adams; Scott R Barnum
Journal:  Mol Immunol       Date:  2007-03-13       Impact factor: 4.407

Review 4.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 5.  Pathogenic and regulatory roles for B cells in experimental autoimmune encephalomyelitis.

Authors:  Monica K Mann; Avijit Ray; Sreemanti Basu; Christopher L Karp; Bonnie N Dittel
Journal:  Autoimmunity       Date:  2012-04-19       Impact factor: 2.815

6.  Multivariate genome wide association and network analysis of subcortical imaging phenotypes in Alzheimer's disease.

Authors:  Xianglian Meng; Jin Li; Qiushi Zhang; Feng Chen; Chenyuan Bian; Xiaohui Yao; Jingwen Yan; Zhe Xu; Shannon L Risacher; Andrew J Saykin; Hong Liang; Li Shen
Journal:  BMC Genomics       Date:  2020-12-29       Impact factor: 3.969

7.  Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease.

Authors:  Paul B Larkin; Paul J Muchowski
Journal:  J Huntingtons Dis       Date:  2012

8.  Evaluation of capsular and acapsular strains of S. aureus in an experimental brain abscess model.

Authors:  Nilufer Esen; Gail Wagoner; Napoleon Philips
Journal:  J Neuroimmunol       Date:  2009-11-10       Impact factor: 3.478

9.  Neurosteroids reduce inflammation after TBI through CD55 induction.

Authors:  Jacob W VanLandingham; Milos Cekic; Sarah Cutler; Stuart W Hoffman; Donald G Stein
Journal:  Neurosci Lett       Date:  2007-08-25       Impact factor: 3.046

10.  Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis.

Authors:  Michael A Flierl; Philip F Stahel; Daniel Rittirsch; Markus Huber-Lang; Andreas D Niederbichler; L Marco Hoesel; Basel M Touban; Steven J Morgan; Wade R Smith; Peter A Ward; Kyros Ipaktchi
Journal:  Crit Care       Date:  2009-02-06       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.